Injectafer Legal News Articles & Interviews

Conshohocken, PA Another Injectafer lawsuit filed in October 2020 joins numerous others filed since 2019, all claiming Vifor Pharma, Ltd., Daiichi Sankyo and its subsidiaries Luitpold Pharmaceuticals and American Regent failed to warn users about the risk of hypophosphatemia—a severe side effect whereby low phosphorous levels are caused by the multiple Injectafer injections.

Santa Clara, CA Hypophosphatemia, an abnormally low level of phosphate in the blood, may be due to longer term use or excess of certain drugs such as bisphosphonates, including Injectafer, but that may depend upon researchers conducting the clinical trials and the amount of the iron-deficiency drug treatment.

West Palm Beach, FL Injectafer, an intravenous iron replacement drug, has recently caught the attention of researchers and the medical community, and in their wake, the legal community. Increasingly, researchers found that the benefits of Injectafer can be outweighed by the serious side effect of severely low phosphorus levels known as hypophosphatemia (HPP). Attorney Brenda Fulmer explains why this drug is still on the market and why patients are filing Injectafer lawsuits.